Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 62.47M P/E - EPS this Y 97.70% Ern Qtrly Grth -
Income 15.79M Forward P/E -0.84 EPS next Y -1,691.70% 50D Avg Chg -16.00%
Sales 87.64M PEG - EPS past 5Y - 200D Avg Chg -45.00%
Dividend N/A Price/Book 1.55 EPS next 5Y - 52W High Chg -74.00%
Recommedations 1.80 Quick Ratio 3.80 Shares Outstanding 7.23M 52W Low Chg 7.00%
Insider Own 6.78% ROA -2.62% Shares Float 5.72M Beta 1.69
Inst Own 45.00% ROE 29.04% Shares Shorted/Prior 234.33K/255.22K Price 0.55
Gross Margin 100.00% Profit Margin 19.36% Avg. Volume 757,020 Target Price 33.60
Oper. Margin 48.39% Earnings Date Nov 5 Volume 1,172,449 Change -5.28%
About Precision BioSciences, Inc.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Precision BioSciences, Inc. News
07:01 AM Precision BioSciences to Participate in Upcoming November Investor Conferences
11/15/24 Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
11/04/24 Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
11/04/24 Precision BioSciences: Q3 Earnings Snapshot
11/04/24 Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
11/01/24 Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
10/29/24 Precision BioSciences to Report Third Quarter Results on November 4, 2024
10/28/24 Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
10/24/24 Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
10/24/24 Precision BioSciences to Report Q3 Earnings: What's in the Cards?
10/24/24 Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
06:01 AM Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
10/16/24 Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
10/04/24 Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
10/03/24 Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
09/30/24 Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
09/20/24 Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09/13/24 Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet
09/12/24 Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
09/11/24 Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock
DTIL Chatroom

User Image Thomas346 Posted - 1 day ago

$DTIL

User Image Blackhole_1987 Posted - 1 day ago

$DTIL will go bankrupt soon. Real garbage.

User Image Blackhole_1987 Posted - 2 days ago

$DTIL Just 46% drop in one year. I think this is a shell company that's why Eli Lilly terminated the partnership. A real garbage.

User Image Blackhole_1987 Posted - 2 days ago

$DTIL Hi Paid Pumper, what will you say now for the crash as I correctly predicted?

User Image Scrood_the_Pooch Posted - 2 days ago

$DTIL Prakash, I thought you said everybody sold out?

User Image Blackhole_1987 Posted - 3 days ago

$DTIL

User Image piton72 Posted - 6 days ago

$DTIL Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B Precision BioSciences (DTIL) has presented preclinical data for PBGENE-HBV, its gene editing therapy for chronic hepatitis B, and outlined its Phase 1 ELIMINATE-B trial design. The preclinical data showed 99% viral DNA editing in non-human primates, effective hepatocyte distribution, and sustained declines in viral biomarkers. The ELIMINATE-B trial will evaluate up to 45 HBeAg-negative patients across five countries, with data expected throughout 2025. The company has received clearance to begin trials in Moldova, with additional regulatory applications pending. The therapy targets approximately 300 million people globally affected by chronic hepatitis B, addressing an unmet need in a multi-billion-dollar market where current treatments achieve functional cure in less than 3% of patients. https://www.stocktitan.net/news/DTIL/precision-bio-sciences-highlights-preclinical-data-and-outlines-rlvsrgnvqy9a.html

User Image valueforme Posted - 6 days ago

$DTIL Have not been here for a while " Investigators and clinical sites in Moldova, the first country to approve a CTA for PBGENE-HBV, have extensive experience executing and enrolling patients in early- and mid-stage hepatitis B clinical trials" Borat's village was filmed in Romania, but this is the first thing that came to my mind when I read this PR

User Image insiderbuyingselling Posted - 2 weeks ago

$DTIL new insider selling: 3012 shares. http://insiderbuyingselling.com/?t=DTIL

User Image Blackhole_1987 Posted - 2 weeks ago

$DTIL

User Image OpenOutcrier Posted - 2 weeks ago

$DTIL (-6.0% pre) Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update https://ooc.bz/l/46784

User Image DonCorleone77 Posted - 2 weeks ago

$DTIL Precision BioSciences reports Q3 EPS ($2.25), consensus ($1.92) Reports Q3 revenue $576,000, consensus $6.36M. The decrease of $12.5M in revenue during the quarter ended September 30 was primarily the result of a $7M decrease in revenue recognized under the Novartis agreement as Precision nears completion of its pre-clinical workplan compared to the three months ended September 30, 2023. In addition, there was a $5.5M decrease in revenue recognized under the prevail agreement during the three months ended September 30, following conclusion of the collaboration in April 2024. "With the clearance of our first clinical trial application (CTA) for our lead program, PBGENE-HBV, we have arrived at the next phase of Precision's journey as a single platform, clinical stage in vivo gene editing company. Our team is moving quickly to dose patients and in parallel is leveraging our robust regulatory package to seek additional regulatory application approvals globally with the aim of rapidly accelerating enrollment in the PBGENE-HBV phase 1 trial," said Michael Amoroso, CEO at Precision BioSciences. "PBGENE-HBV represents the very first clinical stage gene editing program for chronic hepatitis B utilizing a differentiated dual modality targeting the elimination of cccDNA and inactivation of integrated HBV genomes - the root cause of viral persistence in chronic hepatitis B. We look forward to sharing detail on our clinical plans for PBGENE-HBV on November 15 prior to AASLD."

User Image Scrood_the_Pooch Posted - 2 weeks ago

$DTIL Prakash, sleep well tonight.

User Image Jupilerke Posted - 2 weeks ago

$DTIL LFG!

User Image Scrood_the_Pooch Posted - 10/31/24

$DTIL Prakash, is that you and yer Punjabi posse buying?

User Image JVDBNL Posted - 10/31/24

$DTIL Uhhh volume?

User Image Blackhole_1987 Posted - 10/29/24

$DTIL

User Image piton72 Posted - 10/29/24

$DTIL DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. https://www.businesswire.com/news/home/20241029759701/en/

User Image ManikMind Posted - 10/28/24

$DTIL “Final clinical candidate safety data and plans for the Phase 1 trial to be shared in November prior to the American Association for the Study of Liver Diseases meeting. The CTA submissions for PBGENE-HBV are important milestones for Precision as we pioneer this potentially curative therapy for chronic hepatitis B.”

User Image piton72 Posted - 10/28/24

$DTIL Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 https://www.businesswire.com/news/home/20241028524986/en/

User Image Estimize Posted - 10/28/24

Wall St is expecting -59.34% YoY revenue growth for $DTIL in Q3, down from 152.15% in Q2 [Reporting 11/05 BMO] http://www.estimize.com/intr

User Image PenkeTrading Posted - 10/26/24

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Precision BioSciences Inc. Is that bullish or bearish? $DTIL #RsiOversold #NASDAQ

User Image Jmgordon Posted - 10/26/24

$DTIL "Chronic hepatitis B is a significant global health issue, with an estimated 300 million people living with the infection worldwide. Current treatments offer only a small chance of a functional cure and typically require lifelong administration." ...$$

User Image Blackhole_1987 Posted - 10/26/24

$DTIL

User Image Scrood_the_Pooch Posted - 10/25/24

$DTIL https://www.biospace.com/press-releases/precision-biosciences-receives-first-approval-of-clinical-trial-application-to-initiate-pbgene-hbv-first-in-human-study-for-the-treatment-of-chronic-hepatitis-b

User Image Scrood_the_Pooch Posted - 10/25/24

$DTIL https://endpts.com/exclusive-moldova-clears-first-gene-editing-study-for-hbv-in-humans/

User Image Scrood_the_Pooch Posted - 10/25/24

$DTIL https://www.investing.com/news/company-news/precision-biosciences-begins-clinical-trial-for-hepatitis-b-cure-93CH-3680588

User Image Blackhole_1987 Posted - 10/25/24

$DTIL

User Image themacromindset Posted - 10/25/24

$DTIL Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

User Image piton72 Posted - 10/24/24

$DTIL Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress - Stimulating gene editing by homology-directed repair (HDR) has the potential advantage of being able to achieve any type of edit, including gene insertion - ARCUS approach potentially offers broader therapeutic than current gene editing modalities for diseases that require a gain in function https://www.businesswire.com/news/home/20241024715098/en/

Analyst Ratings
HC Wainwright & Co. Buy May 30, 24
HC Wainwright & Co. Buy May 16, 24
Guggenheim Buy Apr 30, 24
HC Wainwright & Co. Buy Apr 17, 24
HC Wainwright & Co. Buy Mar 28, 24
HC Wainwright & Co. Buy Feb 14, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Amoroso Michael President and CEO President and CEO Jan 20 Sell 0.36 137,390 49,460 356,433 01/23/24
Scimeca Dario General Counsel and.. General Counsel and Secretary Jan 20 Sell 0.36 21,287 7,663 151,028 01/23/24
List Alan Chief Medical Office.. Chief Medical Officer Jan 20 Sell 0.36 21,526 7,749 94,982 01/23/24
SMITH J. JEFFERSON Chief Research Offic.. Chief Research Officer Jan 20 Sell 0.37 28,000 10,360 1,987,269 01/23/24
Kelly John Alexander Chief Financial Offi.. Chief Financial Officer Aug 18 Buy 0.48 90,000 43,200 383,340 10/27/23
List Alan Chief Medical Office.. Chief Medical Officer Apr 26 Sell 0.79 7,771 6,139 56,496 04/28/23
Kelly John Alexander Chief Financial Offi.. Chief Financial Officer Mar 17 Buy 0.86 20,000 17,200 245,614 03/21/23
Kelly John Alexander Chief Financial Offi.. Chief Financial Officer Jun 22 Buy 1.50 33,784 50,676 117,701 06/24/22
Scimeca Dario General Counsel and.. General Counsel and Secretary Jun 07 Sell 2.06 9,833 20,256 32,514 06/09/22
List Alan Chief Medical Office.. Chief Medical Officer Apr 26 Sell 2.1 7,775 16,328 18,260 04/28/22
Kelly John Alexander Chief Financial Offi.. Chief Financial Officer Mar 17 Buy 3.08 16,677 51,365 36,189 03/21/22
THOMSON DAVID S. Chief Operating Offi.. Chief Operating Officer Jun 23 Option 1.18 15,000 17,700 126,513 06/23/21
THOMSON DAVID S. Chief Operating Offi.. Chief Operating Officer Jun 23 Sell 10.77 15,000 161,550 111,513 06/23/21
KANE MATTHEW R. President and CEO President and CEO Apr 12 Option 0.04 43,028 1,721 1,962,760 04/12/21
JANTZ DEREK Chief Scientific Off.. Chief Scientific Officer Feb 22 Option 0.04 43,028 1,721 3,943,502 02/22/21
JANTZ DEREK Chief Scientific Off.. Chief Scientific Officer Feb 22 Sell 11.88 16,534 196,424 3,933,839 02/22/21